Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens

Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens

Patients affected by Inflammatory Bowel Disease (IBD) present higher risk for infection and suboptimal response upon vaccination. The immunogenicity of SARS-CoV2 vaccination is still largely unknown in adolescents or young adults affected by IBD (pIBD). We investigated the safety and immunogenicity...

Full description

Bibliographic Details
Main Authors: Nicola Cotugno, Enrica Franzese, Giulia Angelino, Donato Amodio, Erminia Francesca Romeo, Francesca Rea, Simona Faraci, Renato Tambucci, Elisa Profeti, Emma Concetta Manno, Veronica Santilli, Gioacchino Andrea Rotulo, Chiara Pighi, Chiara Medri, Elena Morrocchi, Luna Colagrossi, Giuseppe Rubens Pascucci, Diletta Valentini, Alberto Villani, Paolo Rossi, Paola De Angelis, Paolo Palma
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Vaccines
Subjects:
COVID-19 vaccine
IBD
pediatric
Online Access:https://www.mdpi.com/2076-393X/10/7/1109

Internet

https://www.mdpi.com/2076-393X/10/7/1109

Similar Items